Beyond Air, Inc., a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including serious lung infections and pulmonary hypertension, today announced the termination, for material breach, of the agreement with Circassia Pharmaceuticals, PLC for licensing the commercial rights for LungFit™ PH in the United States and China for use in the hospital setting at NO concentrations < 80 ppm. The agreement was signed January 23, 2019.
Beyond Air is evaluating options for the commercialization of LungFit™ PH, which is still on track for the second half of 2020 in the United States.
For more information, visit www.beyondair.net.
3 Employees Injured by Patient at Halifax Infirmary's Emergency Department
How Architects Shape the Future of Healthcare Facilities
UNC Health, Duke Health Form Partnership for Stand-alone Children's Hospital
Sarasota Memorial Hospital Plans to Build New Facility in North Port
CMMS, Data and the Path to Compliance